All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma

Renal cell carcinoma (RCC) is the most common malignancy of the kidney, representing 80–90% of renal neoplasms, and is associated with a five-year overall survival rate of approximately 74%. The second most common site of metastasis is bone. As patients are living longer due to new RCC targeting age...

Descripción completa

Detalles Bibliográficos
Autores principales: Brozovich, Ava, Garmezy, Benjamin, Pan, Tianhong, Wang, Liyun, Farach-Carson, Mary C., Satcher, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551072/
https://www.ncbi.nlm.nih.gov/pubmed/34745857
http://dx.doi.org/10.1016/j.jbo.2021.100399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551072/
https://www.ncbi.nlm.nih.gov/pubmed/34745857
http://dx.doi.org/10.1016/j.jbo.2021.100399

Ejemplares similares